Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2018

Supporting Information

### Synthesis of Functionalized Pyrroloindolines via Visible-Light-Induced Radical Cascade Reaction: Rapid Synthesis of (±)-Flustraminol B

Kui Wu, Yuliu Du, Zheng Wei and Ting Wang\*

Department of Chemistry, University at Albany, State University of New York, 1400 Washington Ave., Albany, NY 12222, United State

1. General Methods	2
2. General Procedure for Starting Materials	2-5
3. Radical Process Verified Using TEMPO to Trap C3a Radical	5-6
4. General Procedure for Photocatalytic Cyclization	6-17
5. Total Synthesis of (±)-Flustraminol	17-18
6. Emission Quenching Experiments – Stern-Volmer Studies	
7. Light ON – Light OFF Experiments	20
8. Crystal Structure Solution and Refinement	
9. References	22
10. Copies of the Related NMR Spectra	

#### 1. General Methods

All commercially available chemicals were used without further purification unless otherwise noted. Reactions were monitored by thin layer chromatography using TLC silica gel 60-F<sub>254</sub> plates. TLC plates were visualized by UV fluorescence (254 nm) or stained by Cerium Molybdate followed by heating. Purification of the reaction products was carried out by column chromatography using Siliaflash-P60 (40-63  $\mu$ m) silica gel available from Silicycle. <sup>1</sup>H-NMR spectra were recorded on a BRUKER AV-400 (400 MHz) and <sup>13</sup>C-NMR spectra were recorded on a BRUKER AV-400 (100 MHz or 150 MHz). Data for <sup>1</sup>H-NMR are recorded as follows: chemical shift ( $\delta$ , ppm), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, q = quartet), coupling constant(s) in Hz and integration. Data for <sup>13</sup>C-NMR are reported in terms of chemical shift ( $\delta$ , ppm). IR spectra were recorded on a PerkinElmer Spectrum Two IR spectrometer and only major peaks were reported in cm<sup>-1</sup>. High-resolution mass spectral analysis (HRMS) data were obtained using Agilent Technologies 6530 Accurate Mass Q-TOF LC/MS. Irradiation of photochemical reactions was carried out using two 6W PAR38 Green LED flood lamps from ABi LED lighting. Yields refer to chromatographically and spectroscopically purified compounds.

#### 2. General procedure for starting materials

For those known starting materials, not described below, please find the syntheses in previous report<sup>1</sup>.

#### 2.1 N-(2,4-dinitrophenoxy)-N-methyl-2-(1-methyl-1H-indol-3-yl)acetamide (12)



To a solution of indole-3-acetic acid **S1** (15.0 g, 85.7 mmol) in THF (350 mL), NaH (17.1 g, 429 mmol) was added portionwise at 0 °C. The mixture was stirred for 30 minutes and then iodomethane (17.6 mL, 283 mmol) was added dropwise. The reaction was moved to room temperature and the stirring was continued for 16 h. The reaction mixture was then cooled to 0 °C and acidified with 6 N aq. HCl and extracted with EtOAc. The combined organic phase was dried and concentrated. The crude solid was recrystallised from EtOAc/hexane to give the desired product **S2** (15 g, 92%)<sup>2</sup>.

The hydroxamic acid S3 was prepared according to literature's procedure with slight modifications<sup>3</sup>. To a solution of 1-methyl indole-3-acetic acid S2 (300 mg, 1.6 mmol) in DMF 10 ml, CDI (514 mg, 3.2 mmol) was added in one portion. The mixture was stirred for 30 minutes before hydroxylamine hydrochloric salt (330 mg, 4.7 mmol) and imidazole (108 mg, 1.6 mmol) were added. The reaction was allowed to stir for 12 hours at room temperature and then quenched with water. The mixture was extracted with EtOAc. The extracts were combined, dried and concentrated. The crude oil S3 was used without further purification.

The obtained hydroxamic acid **S3** was dissolved in THF (15 mL) and cooled to 0 °C. NaH (190 mg, 4.76 mmol) was added portionwise and the mixture was stirred for 1 hour before 1-fluoro-2,4-dinitrobenzene (200  $\mu$ L, 1.59 mmol) was added. The reaction was moved to room temperature and the stirring was continued for 10 hours. After quenching with water, the mixture was extracted with EtOAc and the combined extracts were dried and concentrated. The residue was purified on silica gel to afford the product **12** (420 mg, 69% over 2 steps); mp 90 °C.<sup>4</sup> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.62 (d, *J* = 2.6 Hz, 1H), 7.85 (dd, *J* = 9.3, 2.6 Hz, 1H), 7.42 (d, *J* = 9.3, 1H), 7.14 (dd, *J* = 11.0, 4.1 Hz, 1H), 7.05 – 6.99 (m, 2H), 6.84 (d, *J* = 9.3 Hz, 1H), 6.77 (s, 1H), 3.98 (s, 2H), 3.54 (s, 3H), 3.36 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  176.0, 155.9, 141.5, 136.3, 135.9, 128.1, 127.5, 127.1, 122.1, 121.3, 119.6, 118.5, 114.3, 109.0, 105.8, 36.2, 32.4, 31.6; ESI HRMS calcd for C<sub>18</sub>H<sub>16</sub>N<sub>4</sub>NaO<sub>6</sub> [M + Na]<sup>+</sup> 407.0962, found 407.0962; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1689, 1684, 1533, 1471, 1342, 1254, 1110, 834, 739.

#### 2-(1,2-Dimethyl-1H-indol-3-yl)-N-(2,4-dinitrophenoxy)-N-methylacetamide (18a)



Following the procedure **2.1**, compound **18a** was obtained as yellow solid (61% over 3 steps); mp 130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.56 (d, *J* = 2.6 Hz, 1H), 7.78 (dd, *J* = 9.3, 2.6 Hz, 1H), 7.31 (d, *J* = 7.8 Hz, 1H), 7.06 (dd, *J* = 7.2, 6.6 Hz, 1H), 7.00 – 6.89 (m, 2H), 6.64 (d, *J* = 9.3 Hz, 1H), 3.94 (s, 2H), 3.41 (s, 3H), 3.33 (s, 3H), 2.23 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  176.2, 156.0, 141.3, 135.8, 135.4, 134.0, 127.7, 126.8, 121.2, 121.2, 119.7, 117.5, 114.1, 108.3, 102.6, 36.1, 31.6, 29.3, 10.1; HRMS calcd for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>6</sub> [M + Na]<sup>+</sup> 421.1119, found 421.1119; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1684, 1604, 1531, 1471, 1341, 1252, 1111, 737.

#### N-(2,4-dinitrophenoxy)-2-(5-fluoro-1,2-dimethyl-1H-indol-3-yl)-N-methylacetamide (19a)



Following the procedure **2.1**, compound **19a** was obtained as yellow solid (57% over 3 steps); mp 145 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.67 (d, J = 2.5 Hz, 1H), 7.93 – 7.88 (m, 1H), 6.99 (dd, J = 9.5, 1.9 Hz, 1H), 6.90 (dd, J = 8.7, 4.2 Hz, 1H), 6.81 (dd, J = 13.8, 5.7 Hz, 2H), 3.88 (s, 2H), 3.42 (s, 3H), 3.34 (s, 3H), 2.21 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  175.7, 158.9, 156.6, 155.9, 141.6, 136.0, 132.6, 128.1, 127.2, 127.1, 121.4, 114.5, 109.3, 109.1, 109.1, 109.0, 102.9, 102.7, 102.6, 36.2, 31.3, 29.5, 10.3; HRMS calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>4</sub>O<sub>6</sub> [M + Na]<sup>+</sup> 439.1024, found 439.1021; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1684, 1605, 1534, 1486, 1343, 1143, 739.

#### N-(2,4-dinitrophenoxy)-2-(6-methoxy-1,2-dimethyl-1H-indol-3-yl)-N-methylacetamide (20a)



Following the procedure **2.1**, compound **20a** was obtained as yellow solid (67% over 3 steps); mp 90 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.54 (d, *J* = 2.6 Hz, 1H), 7.78 (dd, *J* = 9.3, 2.6 Hz, 1H), 7.14 (d, *J* = 8.6 Hz, 1H), 6.64 (d, *J* = 9.3 Hz, 1H), 6.59 (dd, *J* = 8.6, 2.1 Hz, 1H), 6.34 (d, *J* = 1.6 Hz, 1H), 3.86 (s, 2H), 3.77 (s, 3H), 3.31 (s, 6H), 2.15 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  176.1, 156.1, 156.0, 141.2, 136.5, 135.3, 132.7, 127.7, 121.2, 121.1, 118.1, 114.2, 109.2, 102.4, 92.1, 77.5, 77.3, 77.1, 76.8, 36.1, 31.6, 29.2, 10.0; HRMS calcd for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub> [M + Na]<sup>+</sup> 451.1224, found 451.1224; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1684, 1605, 1532, 1489,1342, 1254, 1228, 1114, 833, 738.

### (Z)-N-(2,4-dinitrophenoxy)-2-(1-(4-hydroxybut-2-en-1-yl)-1H-indol-3-yl)-N-methylacetamide (S4)



Following the procedure **2.1**, compound **S4** was obtained as yellow solid (55% over 3 steps); mp 85 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.63 (d, J = 2.5 Hz, 1H), 7.93 (dd, J = 9.3, 2.5 Hz, 1H), 7.44 (t, J = 7.2 Hz, 1H), 7.14 – 6.98 (m, 3H), 6.92 – 6.83 (m, 2H), 5.79 – 5.66 (m, 2H), 4.53 – 4.42 (m, 2H), 4.13 (s, 2H), 3.95 (d, J = 11.4 Hz, 2H), 3.34 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  175.5, 155.9, 141.4, 135.9, 135.7, 132.8, 128.5, 127.4, 126.3, 125.4, 122.1, 121.6, 119.7, 118.6, 114.3, 109.3, 106.2, 62.3, 47.5, 36.1, 31.5; HRMS calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>7</sub> [M + Na]<sup>+</sup> 463.1224, found 463.1223; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1687, 1605, 1533, 1468, 1343, 1256, 1111, 1065, 740.



Following the procedure **2.1**, compound **S5** was obtained as dark yellow oil (66% over 3 steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.61 (d, *J* = 2.6 Hz, 1H), 7.85 (dd, *J* = 9.3, 2.6 Hz, 1H), 7.43 (d, *J* = 7.9 Hz, 1H), 7.17 – 7.09 (m, 1H), 7.06 (d, *J* = 8.0 Hz, 1H), 7.01 (t, *J* = 7.4 Hz, 1H), 6.85 (s, 1H), 6.82 (d, *J* = 9.3 Hz, 1H), 3.99 (s, 2H), 3.91 (q, *J* = 7.3 Hz, 2H), 3.35 (s, 3H), 1.31 (t, *J* = 7.3 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  176.0, 156.0, 141.4, 135.9, 135.4, 128.2, 127.3, 125.7, 121.9, 121.4, 119.5, 118.6, 114.2, 109.0, 105.8, 40.6, 36.1, 31.7, 15.4; ESI HRMS calcd for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>O<sub>6</sub> [M + Na]<sup>+</sup> 421.1119, found 421.1120; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1688, 1604, 1530, 1467, 1339, 1108, 1063, 735.

#### 2-(7-Chloro-1,2-dimethyl-1H-indol-3-yl)-N-(2,4-dinitrophenoxy)-N-methylacetamide (S6)



Following the procedure **2.1**, compound **S6** was obtained as yellow solid (64% over 3 steps); mp 95 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.63 (d, *J* = 2.6 Hz, 1H), 8.01 – 7.89 (m, 1H), 7.18 (d, *J* = 7.7 Hz, 1H), 6.97 (d, *J* = 7.1 Hz, 1H), 6.83 (t, *J* = 7.7 Hz, 1H), 6.72 (d, *J* = 9.3 Hz, 1H), 3.91 (s, 2H), 3.80 (s, 3H), 3.33 (s, 3H), 2.23 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  175.8, 155.8, 141.4, 136.1, 135.29, 131.0, 129.6, 127.8, 122.9, 121.3, 120.3, 116.1, 116.1, 113.8, 103.4, 36.2, 32.1, 31.4, 10.5; HRMS calcd for C<sub>19</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>6</sub> [M + Na]<sup>+</sup> 455.0729, found 455.0725; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1683, 1604, 1530, 1304, 1111, 1066, 734.

#### 3. Radical Process Verified Using TEMPO to Trap C3a Radical



To a solution of indol-3-yl acetamide **12** (38.4 mg, 0.1 mmol) and TEMPO (31 mg, 0.2 mmol) in  $CH_2Cl_2$  (0.1 M) in a vial was added Eosin Y (2 mol %). Nitrogen was bubbled through the solution for 5 minutes. DIPEA (35  $\mu$ L, 0.2 mmol) was added via syringe and nitrogen was bubbled through the solution for another 10 minutes. The vial was then capped and irradiated under green LEDs for 10 hours. The reaction mixture was concentrated and directly purified on silica gel to give the TEMPO derivative **13** as colorless oil (29 mg, 79%). <sup>1</sup>H NMR (400 MHz,

CDCl<sub>3</sub>)  $\delta$ 7.26 (d, J = 8.0 Hz, 1H), 7.19 (td, J = 8.0, 1.2 Hz, 1H), 6.79 (td, J = 7.5, 0.8 Hz, 1H), 6.46 (d, J = 8.0 Hz, 1H), 5.77 (s, 1H), 3.30 – 3.19 (m, 1H), 3.09 (s, 3H), 2.99 (s, 3H), 2.96 – 2.86 (m, 1H), 1.55 – 1.27 (m, 6H), 1.13 (s, 3H), 0.99 (s, 3H), 0.37 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.5, 150.69, 132.8, 129.9, 124.1, 118.9, 108.1, 88.1, 86.8, 60.0, 59.3, 46.6, 40.8, 40.3, 36.7, 33.3, 32.9, 28.3, 20.6, 20.3, 16.9; ESI HRMS calcd for C<sub>21</sub>H<sub>31</sub>N<sub>3</sub>NaO<sub>2</sub> [M + Na]<sup>+</sup> 380.2308, found 380.2310; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 2927, 1696, 1609, 1492, 1288, 1260, 974, 744.

#### 4. General Procedure for Photocatalytic Cyclization

#### 4.1. 1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (14)



To a solution of indol-3-yl acetamide **12** (38.4 mg, 0.1 mmol) and *t*-BuSH (20 mg, 0.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.1 M) in a vial was added Eosin Y (2 mol %). Nitrogen was bubbled through the solution for 5 minutes. DIPEA (35  $\mu$ L, 0.2 mmol) was added via syringe and nitrogen was bubbled through the solution for another 10 minutes. The vial was then capped and irradiated under green LED for 10 hours. The reaction mixture was concentrated and directly purified on silica gel to give the title compound (**14**) as colorless solid (16 mg, 78%); mp 130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.14 (t, *J* = 7.7 Hz, 1H), 7.06 (d, *J* = 7.3 Hz, 1H), 6.74 (t, *J* = 7.4 Hz, 1H), 6.47 (d, *J* = 7.8 Hz, 1H), 5.07 (d, *J* = 8.0 Hz, 1H), 4.07 – 3.97 (m, 1H), 3.07 (s, 3H), 2.94 (s, 3H), 2.92 – 2.85 (m, 1H), 2.59 (dd, *J* = 17.2, 3.2 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  173.4, 150.2, 131.0, 128.7, 124.1, 118.7, 107.5, 85.8, 38.5, 36.8, 35.7, 28.4; ESI HRMS calcd for C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O [M + Na]<sup>+</sup> 225.0998, found 225.1002; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 2923, 1679, 1605, 1492, 1398, 1286, 1227, 1006, 745, 694, 662, 593.

#### 5-Bromo-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (16b)



Following the procedure **4.1**, compound **16a** (46.2 mg) gave **16b** as yellowish solid (19.2 mg, 68%) mp 90 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.22 (d, *J* = 8.3 Hz, 1H), 7.14 (s, 1H), 6.31 (d, *J* = 8.3 Hz, 1H), 5.08 (d, *J* = 8.0 Hz, 1H), 4.05 – 3.93 (m, 1H), 3.05 (s, 3H), 2.94 (s, 3H), 2.88 (dd, *J* = 17.3, 10.1 Hz, 1H), 2.55 (dd, *J* = 17.3, 3.2 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  173.1, 149.3, 133.2, 131.3, 127.1, 110.2, 108.7, 85.7, 38.3, 36.5, 35.5, 28.5; ESI HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrN<sub>2</sub>O [M + Na]<sup>+</sup> 303.0103, found 303.0101; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1674, 1601, 1491,1419, 1398, 1271, 1228, 1086, 1007, 804.



Following the procedure **4.1**, compound **17a** (41.4 mg) gave **17b** as yellowish solid (18.3 mg, 79%); mp 108 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.77 – 6.65 (m, 2H), 6.42 (d, *J* = 8.3 Hz, 1H), 5.00 (d, *J* = 8.0 Hz, 1H), 4.08 – 3.94 (m, 1H), 3.74 (s, 3H), 3.01 (s, 3H), 2.92 (d, *J* = 7.1 Hz, 3H), 2.91 – 2.82 (m, 1H), 2.55 (dd, *J* = 17.2, 3.1 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  173.2, 153.7, 144.7, 132.6, 113.4, 111.3, 108.8, 86.7, 56.0, 38.8, 37.3, 36.7, 28.2; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1102; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1676, 1493, 1422, 1275, 1226, 1027, 1007, 974, 803, 712.

#### 1,8,8a-Trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (18b)



Following the procedure **4.1**, compound **18a** (39.8 mg) gave **18b** as yellowish oil (17.7 mg, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.14 (t, *J* = 7.7 Hz, 1H), 7.04 (d, *J* = 7.2 Hz, 1H), 6.71 (t, *J* = 7.4 Hz, 1H), 6.37 (d, *J* = 7.8 Hz, 1H), 3.61 (d, *J* = 9.0 Hz, 1H), 2.98 (s, 3H), 2.90 (dd, *J* = 17.0, 9.1 Hz, 1H), 2.84 (s, 3H), 2.66 (d, *J* = 17.1 Hz, 1H), 1.63 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.7, 149.6, 129.6, 128.7, 123.9, 118.1, 106.0, 87.3, 46.4, 36.2, 30.0, 26.0, 20.3; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O [M + Na]<sup>+</sup> 239.1155, found 239.1154; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1672, 1607, 1492, 1417, 1393, 1110, 1090, 796, 691.

#### 5-Fluoro-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (19b)



Following the procedure **4.1**, compound **19a** (41.6 mg) gave **19b** as yellowish oil (18.2 mg, 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.86 – 6.71 (m, 2H), 6.22 (dd, *J* = 8.4, 4.0 Hz, 1H), 3.56 (dd, *J* = 15.7, 7.6 Hz, 1H), 2.92 (s, 3H), 2.90 – 2.82 (m, 1H), 2.80 (s, 3H), 2.58 (dd, *J* = 17.0, 2.1 Hz, 1H), 1.59 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.3, 157.7, 155.3, 145.9, 131.0, 130.9, 114.5, 114.3, 111.8, 111.5, 106.1, 106.0, 87.8, 46.3, 46.3, 35.9, 30.4, 26.0, 20.2; ESI HRMS calcd for C<sub>13</sub>H<sub>15</sub>FN<sub>2</sub>O [M + Na]<sup>+</sup> 257.1061, found 257.1060; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1680, 1494, 1393, 1268, 1235, 1113, 1089, 889.



Following the procedure **4.1**, compound **20a** (42.8 mg) gave **20b** as yellowish oil (18.5 mg, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.90 (dd, J = 8.0, 1.0 Hz, 1H), 6.21 (dd, J = 8.0, 2.2 Hz, 1H), 5.94 (d, J = 2.2 Hz, 1H), 3.76 (s, 3H), 3.54 (t, J = 13.1 Hz, 1H), 2.95 (s, 3H), 2.87 (dd, J = 17.4, 8.5 Hz, 1H), 2.82 (s, 3H), 2.64 – 2.54 (m, 1H), 1.59 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.7, 161.1, 150.9, 124.1, 122.0, 101.8, 93.7, 87.9, 55.4, 45.7, 36.4, 29.9, 25.9, 20.3; ESI HRMS calcd for C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 269.1260, found 269.1261; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1676, 1619, 1501, 1389, 1229, 1084, 945, 816, 729, 688.

#### 4.2. 3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (21)



To a solution of indol-3-yl acetamide **12** (38.4 mg, 0.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.1 M) in a vial was added Eosin Y (2 mol %). DIPEA (35  $\mu$ L, 0.2 mmol) was added via syringe and then irradiated under green LED in the open air for 10 hours. The reaction mixture was concentrated and directly purified on silica gel to give the title compound **(21)** as white solid (17 mg, 75%); mp 85 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.30 – 7.24 (m, 2H), 6.82 (td, *J* = 7.4, 0.7 Hz, 1H), 6.56 (d, *J* = 7.9 Hz, 1H), 4.78 (s, 1H), 3.10 (s, 3H), 2.95 (s, 3H), 2.93 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.8, 150.0, 131.2, 130.9, 123.6, 119.2, 108.6, 92.5, 80.0, 43.5, 36.0, 28.1; ESI HRMS calcd for C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 241.0947, found 241.0948; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 3331, 2723, 1666, 1609, 1492, 1398,1281, 1083, 987, 746.

#### 3a-Hydroxy-1,8-dimethyl-5-phenyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (22)



Following the procedure **4.2**, 46.0 mg starting material gave **22** as yellowish oil (22.9 mg, 78%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.04 (d, J = 7.4 Hz, 1H), 6.75 (d, J = 7.4 Hz, 1H), 4.63 (s, 1H), 3.48 (s, 1H), 3.13 (s, 3H), 3.00 (dt, J = 15.7, 8.0 Hz, 1H), 2.94 – 2.76 (m, 8H), 2.06 (ddt, J = 37.7, 20.8, 8.5 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.6, 148.7, 146.8, 130.6, 126.9, 121.9, 116.9, 93.9, 80.0, 43.8, 39.0, 32.6, 30.6, 27.3, 25.5; ESI HRMS calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 317.1260, found 317.1264; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1667, 1616, 1485, 1398, 1282, 990, 908, 728. 7-Ethyl-3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (23)



Following the procedure **4.2**, 41.2 mg starting material gave **23** as yellowish oil (16.7 mg, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.12 (dd, J = 11.1, 7.7 Hz, 2H), 6.93 (t, J = 7.5 Hz, 1H), 4.63 (s, 1H), 3.10 (s, 3H), 2.89 (t, J = 11.0 Hz, 2H), 2.84 (s, 3H), 2.79 – 2.69 (m, 1H), 2.62 (dq, J = 14.9, 7.4 Hz, 1H), 1.24 (t, J = 7.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 149.1, 134.4, 131.3, 130.8, 122.7, 121.5, 94.2, 80.2, 43.3, 41.7, 26.7, 24.7, 13.8; ESI HRMS calcd for C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 269.1260, found 269.1267; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1667, 1482, 1453, 1417, 1397, 1285, 1087, 1036, 974, 755.

### 5b-hydroxy-8,9-dimethyl-2,3,5b,6,8a,9-hexahydro-1H-cyclopenta[g]pyrrolo[2,3-b]indol-7(8H)-one (24)



Following the procedure **4.2**, 84.8 mg starting material gave **24** as yellowish oil (43.3 mg, 84%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.04 (d, J = 7.4 Hz, 1H), 6.75 (d, J = 7.4 Hz, 1H), 4.63 (s, 1H), 3.48 (s, 1H), 3.13 (s, 3H), 3.00 (dt, J = 15.7, 8.0 Hz, 1H), 2.94 – 2.76 (m, 8H), 2.06 (ddt, J = 37.7, 20.8, 8.5 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.6, 148.7, 146.8, 130.6, 126.9, 121.9, 116.9, 93.9, 80.0, 43.8, 39.0, 32.6, 30.6, 27.3, 25.5; ESI HRMS calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 281.1260, found 281.1267; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1665, 1595, 1467, 1416, 1397, 1278, 1073, 1006, 729.

#### 3a-hydroxy-1,4,8-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (25)



Following the procedure **4.2**, 75.0 mg starting material gave **25** as yellowish oil (33.3 mg, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.13 (t, *J* = 7.7 Hz, 1H), 6.58 (d, *J* = 7.5 Hz, 1H), 6.38 (d, *J* = 7.9 Hz, 1H), 4.74 (s, 1H), 3.05 (s, 3H), 3.00 – 2.91 (m, 5H), 2.73 (d, *J* = 3.4 Hz, 1H), 2.35 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.3, 150.5, 135.2, 130.5, 128.5, 121.2, 106.2, 93.7, 80.1, 43.0, 36.6, 28.1, 17.4; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1109; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1665, 1598, 1480, 1284, 982, 749.

#### 3a-Hydroxy-1,5,8-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (26)



Following the procedure **4.2**, 75.0 mg starting material gave **26** as yellowish oil (33.3 mg, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.13 – 7.00 (m, 2H), 6.47 (d, *J* = 8.0 Hz, 1H), 4.72 (s, 1H), 3.05 (s, 3H), 2.93 (s, 3H), 2.87 (t, *J* = 4.4 Hz, 2H), 2.84 (d, *J* = 6.3 Hz, 1H), 2.28 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 148.0, 131.4, 131.3, 128.9, 124.1, 108.9, 93.1, 80.1, 43.6, 36.8, 28.0, 20.6; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1104; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1666, 1501, 1398, 1281, 1082, 1048, 995, 806.

#### 3a-Hydroxy-1,6,8-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (27)



Following the procedure **4.2**, 40.0 mg starting material gave **27** as yellowish oil (15.0 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.14 (d, *J* = 7.5 Hz, 1H), 6.62 (d, *J* = 7.5 Hz, 1H), 6.37 (s, 1H), 4.74 (s, 1H), 3.07 (s, 3H), 2.92 (s, 3H), 2.89 (s, 2H), 2.76 (s, 1H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.0, 150.2, 141.0, 128.7, 123.4, 120.0, 109.4, 92.8, 79.7, 43.6, 36.1, 28.0, 21.8; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1110; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1670, 1515, 1499, 1287, 1084, 10501, 987.

#### 3a-hydroxy-1,7,8-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (28)



Following the procedure **4.2**, 40.0 mg starting material gave **28** as yellowish oil (15.3 mg, 66%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.15 (d, *J* = 7.4 Hz, 1H), 7.08 (d, *J* = 7.4 Hz, 1H), 6.90 (t, *J* = 7.4 Hz, 1H), 4.66 (s, 1H), 3.11 (s, 3H), 2.97 – 2.84 (m, 5H), 2.59 (s, 1H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 149.7, 134.0, 133.2, 124.5, 122.4, 121.5, 94.2, 80.3, 43.3, 41.3, 26.8, 18.5; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1107; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1666, 1469, 1398, 1285, 1265, 1076, 1009, 974, 755.

#### 4-bromo-3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (29)



Following the procedure **4.2**, 46.3 mg starting material gave **29** as yellowish oil (21.3 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.07 (t, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 7.9 Hz, 1H), 6.47 (d, *J* = 8.0 Hz, 1H), 4.83 (s, 1H), 3.21 (d, *J* = 18.0 Hz, 1H), 3.18 (s, 1H), 3.08 (s, 3H), 2.97 (s, 3H), 2.93 (d, *J*  = 17.9 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 152.0, 131.9, 129.1, 122.3, 118.7, 107.5, 92.4, 80.6, 43.3, 36.2, 28.2; ESI HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 319.0053, found 319.0047; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1667, 1598, 1573, 1479, 1426, 1399, 1286, 980, 733.

#### 5-bromo-3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (30)



Following the procedure **4.2**, 50.0 mg **16a** gave **30** as yellowish oil (23.4 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.36 (d, J = 1.9 Hz, 1H), 7.32 (dd, J = 8.4, 2.0 Hz, 1H), 6.41 (d, J = 8.4 Hz, 1H), 4.78 (s, 1H), 3.06 (s, 4H), 2.93 (d, J = 8.4 Hz, 3H), 2.92 – 2.80 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.6, 149.0, 133.5, 133.3, 126.8, 110.6, 110.0, 92.6, 79.6, 43.5, 35.9, 28.2; ESI HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 319.0053, found 319.0050; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1671, 1604, 1491, 1399, 1268, 1099, 992, 810.

#### 6-bromo-3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (31)



Following the procedure **4.2**, 54.0 mg starting material gave **31** as yellowish oil (21.3 mg, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.11 (d, *J* = 7.9 Hz, 1H), 6.90 (dd, *J* = 7.9, 1.6 Hz, 1H), 6.66 (s, 1H), 4.79 (d, *J* = 0.9 Hz, 1H), 3.07 (s, 4H), 2.93 (s, 3H), 2.86 (t, *J* = 10.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 151.1, 130.4, 124.9, 124.5, 121.8, 111.5, 92.4, 79.3, 43.5, 35.5, 28.2; ESI HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 319.0053, found 319.0061; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1753, 1672, 1603, 1537, 1491, 1414, 1260, 1137, 983, 831, 737.

#### 7-bromo-3a-hydroxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (32)



Following the procedure **4.2**, 50.0 mg starting material gave **32** yellowish oil (25.3 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.07 (t, *J* = 8.0 Hz, 1H), 6.87 (d, *J* = 7.9 Hz, 1H), 6.47 (d, *J* = 8.0 Hz, 1H), 4.83 (s, 1H), 3.21 (d, *J* = 18.0 Hz, 1H), 3.18 (s, 1H), 3.08 (s, 3H), 2.97 (s, 3H), 2.93 (d, *J* = 17.9 Hz, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 152.0, 131.9, 129.1, 122.3, 118.7, 107.5, 92.4, 80.6, 43.3, 36.2, 28.2; ESI HRMS calcd for C<sub>12</sub>H<sub>13</sub>BrN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 319.0053, found 319.0060; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1669, 1600, 1467, 1416, 1286, 1252, 1090, 1048, 998, 746.

#### 3a-hydroxy-4-methoxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (33)



Following the procedure **4.2**, 50.0 mg starting material gave **33** as yellowish oil (22.5 mg, 72%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.20 (t, *J* = 8.0 Hz, 1H), 6.33 (d, *J* = 7.9 Hz, 1H), 6.21 (d, *J* = 7.7 Hz, 1H), 4.78 (d, *J* = 1.6 Hz, 1H), 3.85 (s, 3H), 3.19 (d, *J* = 17.6 Hz, 1H), 3.08 (s, 3H), 2.95 (s, 3H), 2.87 (d, *J* = 14.5 Hz, 1H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  172.3, 156.3, 151.7, 132.2, 116.9, 102.3, 101.7, 92.3, 79.6, 55.3, 43.5, 36.4, 28.0; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 271.1053, found 271.1057; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1669, 1606, 1484, 1398, 1295, 1258, 1144, 1068, 1048, 988, 754.

3a-hydroxy-5-methoxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (34)

MeC



Following the procedure **4.2**, compound **17a** (50.0 mg) gave **34** as yellowish oil (20.3 mg, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.86 (d, *J* = 2.5 Hz, 1H), 6.82 (dd, *J* = 8.5, 2.6 Hz, 1H), 6.51 (d, *J* = 8.5 Hz, 1H), 4.68 (s, 1H), 3.75 (s, 3H), 3.18 (s, 1H), 3.02 (s, 3H), 2.91 (d, *J* = 6.8 Hz, 3H), 2.85 (d, *J* = 4.1 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.8, 154.0, 144.5, 132.4, 116.7, 110.4, 109.4, 93.8, 80.2, 56.0, 43.7, 37.8, 28.0; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 271.1053, found 271.1054; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1665, 1494, 1274, 1218, 1026, 994.

#### 3a-hydroxy-6-methoxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (35)



Following the procedure **4.2**, 45.0 mg starting material gave **35** as yellowish oil (21.6 mg, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.13 (d, *J* = 8.2 Hz, 1H), 6.31 (d, *J* = 8.2 Hz, 1H), 6.06 (s, 1H), 4.73 (s, 1H), 3.77 (s, 3H), 3.05 (s, 3H), 2.89 (s, 3H), 2.85 (s, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 172.0, 162.5, 151.5, 124.3, 124.0, 104.1, 95.0, 92.9, 79.4, 55.4, 43.6, 35.7, 28.0; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 271.1053, found 271.1054; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>)1670, 1619, 1501, 1236, 1084, 987, 829.

3a-hydroxy-7-methoxy-1,8-dimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (36)



Following the procedure **4.2**, 56.0 mg starting material gave **36** as yellowish oil (26.8 mg, 83%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.90 (dd, J = 9.8, 4.3 Hz, 2H), 6.81 (d, J = 6.8 Hz, 1H), 4.62 (s, 1H), 3.84 (s, 3H), 3.18 (s, 3H), 3.05 (s, 1H), 2.89 (s, 3H), 2.86 (s, 2H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$ 171.1, 148.1, 139.4, 134.5, 122.7, 116.0, 113.2, 94.2, 80.8, 55.6, 43.5, 40.3, 27.2; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 271.1053, found 271.1056; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1665, 1593, 1492, 1452, 1418, 1398, 1285, 1232, 999.

### (Z)-3a-hydroxy-8-(4-hydroxybut-2-en-1-yl)-1-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (37)



Following the procedure **4.2**, compound **S4** (44.0 mg) gave **37** as yellowish oil (17.8 mg, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.21 (dd, J = 13.8, 7.3 Hz, 2H), 6.80 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 5.79 (dt, J = 15.5, 4.7 Hz, 1H), 5.72 – 5.59 (m, 1H), 4.83 (s, 1H), 4.13 (dd, J = 16.2, 4.7 Hz, 1H), 4.00 (ddd, J = 28.1, 14.3, 4.3 Hz, 2H), 3.93 – 3.75 (m, 2H), 2.86 (d, J = 4.8 Hz, 5H), 2.69 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.2, 149.0, 133.0, 132.3, 130.5, 125.2, 124.0, 119.8, 110.3, 90.0, 79.7, 61.8, 51.0, 43.7, 27.7; ESI HRMS calcd for C<sub>15</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 297.1210, found 297.1208; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1676, 1603, 1489, 1293, 991, 748.

#### 8-Allyl-3a-hydroxy-1-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (38)



Following the procedure **4.2**, 41.0 mg starting material gave **38** as yellowish oil (17.7 mg, 75%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.28 – 7.16 (m, 2H), 6.81 (t, *J* = 7.0 Hz, 1H), 6.59 (d, *J* = 7.9 Hz, 1H), 5.87 (ddd, *J* = 22.2, 10.4, 5.4 Hz, 1H), 5.24 (dd, *J* = 19.0, 14.3 Hz, 2H), 4.85 (s, 1H), 4.04 (d, *J* = 16.6 Hz, 1H), 3.89 (dd, *J* = 16.6, 5.5 Hz, 1H), 3.25 (s, 1H), 2.87 (d, *J* = 5.3 Hz, 5H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.8, 149.4, 133.6, 131.9, 130.7, 123.7, 119.7, 117.7, 109.8, 91.0, 80.0, 52.7, 43.6, 27.8; ESI HRMS calcd for C<sub>14</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 267.1104, found 267.1109; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1674, 1605, 1474, 1461, 1279, 1230, 1061, 956, 731.

#### 8-Ethyl-3a-hydroxy-1-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (39)



Following the procedure **4.2**, compound **S5** (40.0 mg) gave **39** as yellowish solid (17.7 mg, 76%); mp 130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.24 – 7.16 (m, 2H), 6.77 (td, *J* = 7.4, 0.8 Hz, 1H), 6.58

(d, J = 8.0 Hz, 1H), 4.79 (s, 1H), 3.50 (dq, J = 14.4, 7.2 Hz, 1H), 3.31 (dq, J = 14.3, 7.1 Hz, 1H), 2.86 – 2.80 (m, 5H), 1.17 (t, J = 7.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.9, 149.1, 132.3, 130.6, 123.8, 119.4, 109.8, 90.3, 79.9, 43.8, 43.4, 27.5, 13.0; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1103; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1665, 1607, 1487, 1398, 1268, 1083, 1049, 990, 746.

#### 8-benzyl-3a-hydroxy-1-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (40)



Following the procedure **4.2**, 46.0 mg starting material gave **40** as yellow solid (20.6 mg, 70%); mp 105 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31 (dt, *J* = 20.3, 6.7 Hz, 6H), 7.19 (dd, *J* = 11.1, 4.2 Hz, 1H), 6.84 (t, *J* = 7.4 Hz, 1H), 6.55 (d, *J* = 8.0 Hz, 1H), 4.92 (s, 1H), 4.59 (dd, *J* = 44.8, 16.2 Hz, 2H), 3.01 – 2.87 (m, 2H), 2.79 (s, 1H), 2.74 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.8, 149.7, 137.8, 131.8, 130.9, 128.8, 127.6, 127.1, 123.8, 119.9, 109.9, 91.4, 80.1, 54.1, 43.5, 27.9; ESI HRMS calcd for C<sub>18</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 317.1260, found 317.1260; 1665, 1607, 1491, 1395, 1273, 1229, 916, 744, 692.

3a-Hydroxy-1-methyl-8-(triisopropylsilyl)-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)one (41)



Following the procedure **4.2**, 55.0 mg starting material gave **41** as yellowish oil (25.2 mg, 67%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.30 (d, J = 7.4 Hz, 1H), 7.24 – 7.14 (m, 1H), 6.90 (dd, J = 12.0, 4.7 Hz, 2H), 5.21 (s, 1H), 2.99 (q, J = 16.4 Hz, 2H), 2.84 (s, 3H), 2.01 (s, 1H), 1.46 (dq, J = 14.7, 7.5 Hz, 3H), 1.22 (d, J = 7.5 Hz, 9H), 1.11 (d, J = 7.5 Hz, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 171.0, 150.5, 134.1, 130.5, 124.1, 120.8, 114.4, 85.9, 81.0, 41.6, 26.8, 18.9, 18.7, 13.1; ESI HRMS calcd for C<sub>20</sub>H<sub>32</sub>N<sub>2</sub>O<sub>2</sub>Si [M + Na]<sup>+</sup> 383.2125, found 383.2121; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1670, 1609, 1489, 1286, 1157, 991, 746.

3a-Hydroxy-8-(methoxymethyl)-1-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (42)



Following the procedure **4.2**, 50.0 mg starting material gave **42** as yellowish oil (24.2 mg, 81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31 – 7.18 (m, 2H), 6.90 (t, *J* = 7.3 Hz, 1H), 6.75 (d, *J* = 7.9 Hz, 1H), 4.90 – 4.75 (m, 2H), 4.50 (d, *J* = 10.5 Hz, 1H), 4.06 (s, 1H), 3.24 (s, 3H), 2.84 (s, 2H), 2.81 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.5, 147.7, 133.0, 130.6, 124.3, 121.4, 110.9, 90.0, 82.2, 79.8, 55.3, 43.0, 27.1; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 271.1053, found 271.1055; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1668, 1608, 1487, 1398, 1157, 1071, 994, 746.

#### 1-(3a-hydroxy-8-methyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-1(2H)-yl)ethanone (43)



Following the procedure **4.2**, 40.0 mg starting material gave **43** as yellowish oil (13.4 mg, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 – 7.18 (m, 2H), 6.75 (dt, *J* = 7.4, 5.5 Hz, 1H), 6.48 (t, *J* = 6.1 Hz, 1H), 5.45 (s, 1H), 3.75 (ddd, *J* = 10.5, 7.7, 5.1 Hz, 1H), 3.38 (dt, *J* = 10.4, 7.7 Hz, 1H), 2.99 (s, 3H), 2.39 (dt, *J* = 12.9, 7.9 Hz, 1H), 2.30 (ddd, *J* = 11.4, 6.5, 4.6 Hz, 1H), 2.06 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  171.0, 150.9, 130.3, 130.1, 122.7, 118.1, 107.3, 88.3, 86.4, 47.5, 38.4, 34.5, 22.4; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1105; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1612, 1491, 1417, 1297, 1196, 1129, 1050, 945, 745.

#### 3a-hydroxy-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (44)



Following the procedure **4.2**, compound **18a** (57.0 mg) gave **44** as yellowish oil (17.7 mg, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.30 (dt, J = 8.5, 4.2 Hz, 1H), 7.26 – 7.21 (m, 1H), 6.78 (t, J = 7.4Hz, 1H), 6.48 (d, J = 7.9 Hz, 1H), 3.03 – 2.96 (m, 4H), 2.86 (d, J = 16.9 Hz, 1H), 2.79 (s, 3H), 2.10 (s, 1H), 1.56 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 148.9, 131.0, 130.0, 124.1, 118.5, 107.0, 88.9 81.2, 41.5, 29.9, 25.9, 15.0; ESI HRMS calcd for C<sub>13</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 255.1104, found 255.1100; 1666, 1609, 1494, 1395, 1101, 1064, 991, 914, 744.

## 3a-hydroxy-6-methoxy-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (45)



Following the procedure **4.2**, compound **20a** (50.0 mg) gave **45** as yellowish oil (21.7 mg, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.16 (t, J = 8.6 Hz, 1H), 6.26 (dd, J = 8.2, 2.1 Hz, 1H), 5.99 (d, J = 2.1 Hz, 1H), 3.77 (s, 3H), 2.96 (s, 3H), 2.83 (dd, J = 49.9, 16.9 Hz, 2H), 2.74 (d, J = 6.1 Hz, 3H), 2.65 (s, 1H), 1.51 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.4, 162.6, 150.4, 124.8, 122.9, 103.0, 93.8, 89.5, 80.7, 55.4, 41.6, 29.9, 25.8, 15.0; ESI HRMS calcd for C<sub>14</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub> [M + Na]<sup>+</sup> 285.1210, found 285.1208; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1667, 1619, 1498, 1419, 1393, 1231, 1091, 1064, 952.

#### 5-fluoro-3a-hydroxy-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (46)



Following the procedure **4.2**, compound **19a** (40.0 mg) gave **46** as yellowish oil (18.5 mg, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  6.99 (d, J = 7.6 Hz, 1H), 6.91 (t, J = 8.7 Hz, 1H), 6.39 – 6.31 (m, 1H), 2.98 (d, J = 10.8 Hz, 1H), 2.94 (s, 3H), 2.91 – 2.77 (m, 2H), 2.74 (s, 3H), 1.51 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  170.2, 157.7, 155.3, 145.1, 131.4, 131.3, 117.1, 116.9, 111.6, 111.3, 107.4, 107.4, 89.6, 81.0, 41.7, 30.4, 26.0, 14.8; ESI HRMS calcd for C<sub>13</sub>H<sub>15</sub>FN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 273.1010, found 273.1008; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1667, 1498, 1396, 1267, 1103, 1065, 893, 807.

#### 7-chloro-3a-hydroxy-1,8,8a-trimethyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (47)



Following the procedure **4.2**, compound **S6** (51.0 mg) gave **47** as yellowish oil (21.7 mg, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.18 – 7.14 (m, 2H), 6.75 (td, J = 7.7, 1.6 Hz, 1H), 3.25 – 3.22 (m, 3H), 2.78 (td, J = 17.0, 10.2 Hz, 2H), 2.71 (d, J = 7.1 Hz, 3H), 1.51 (d, J = 1.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  169.6, 145.6, 135.0, 132.5, 122.9, 121.1, 117.1, 89.6, 81.1, 41.5, 33.5, 24.9, 14.9; ESI HRMS calcd for C<sub>13</sub>H<sub>15</sub>ClN<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 289.0714, found 289.0712; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1666, 1475, 1419, 1395, 1272, 1107, 1064, 737.

#### 4.3 Reduction of TEMPO derivative (13) to compound (21)



A solution of TEMPO derivative **13** in HOAc/H<sub>2</sub>O/THF (0.3 mL: 0.1 mL: 0.1 mL) under argon was added activated zinc powder in one portion. The suspension was heated to 50  $^{\circ}$ C for 24 hours and then cooled to room temperature and filtered. The filtrate was poured into water and the mixture was extracted with EtOAc. The combined organic layer was washed with saturated NaHCO<sub>3</sub> aqueous solution, water and brine and dried. Then the solvent was evaporated and the crude product was purified on silica gel to give compound **21** as colorless oil (69%).

#### 5. Total Synthesis of (±)-Flustraminol



To a solution of 6-bromoindole-3-acetic acid **48** (310 mg, 1.22 mmol) in THF (15 mL), NaH (146 mg, 3.66 mmol) was added portionwise. The mixture was stirred for 30 minutes at 0 °C and then dimethylallylbormide **49** (236 mg, 1.59 mmol) was added dropwise. The reaction was moved to room temperature and the stirring was continued for 16 hours. The reaction mixture was then cooled to 0 °C and acidified with 6 N aq. HCl and extracted with EtOAc. The combined organic phase was dried and concentrated. The residue was purified on silica gel to give product **50** as dark yellow oil (385 mg, 98%).<sup>2</sup>

To a solution of the obtained indole-3-acetic acid **50** (100 mg, 0.31 mmol) and O-(2,4dinitrophenyl)-N-methylhydroxylamine **51** (80 mg, 0.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), HATU (118 mg, 0.31 mmol) was added. DIPEA (154 uL, 0.93 mmol) was added via syringe while the mixture was stirred vigorously. The reaction was allowed to stir for 12 hours and then quenched with water. The mixture was extracted with EtOAc. The combined extracts were dried and concentrated. The residue was purified on silica gel to give the product **52** as orange solid (120 mg, 75%); mp 95 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.67 (d, *J* = 2.3 Hz, 1H), 8.01 (dd, *J* = 9.3, 2.0 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 7.24 (s, 1H), 7.10 – 7.05 (m, 1H), 6.97 (d, *J* = 9.3 Hz, 1H), 6.83 (s, 1H), 5.12 (t, *J* = 6.5 Hz, 1H), 4.39 (d, *J* = 6.9 Hz, 2H), 3.92 (s, 2H), 3.34 (s, 3H), 1.78 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  175.5, 155.9, 141.6, 137.4, 136.5, 136.1, 128.8, 127.0, 126.3, 122.6, 121.7, 120.0, 118.7, 115.4, 114.5, 112.4, 106.1, 43.9, 36.2, 31.1, 25.6, 18.0; ESI HRMS calcd for C<sub>22</sub>H<sub>21</sub>BrN<sub>4</sub>O<sub>6</sub> [M + Na]<sup>+</sup> 539.0537, found 539.0545; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 3110, 2933, 1690, 1605, 1533, 1468, 1342, 1255, 1231, 1163, 1100, 834, 770.

# 6-bromo-3a-hydroxy-1-methyl-8-(3-methylbut-2-en-1-yl)-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indol-2(1H)-one (53)

Following the procedure **4.2**, compound **52** (40.0 mg) gave **53** as yellowish oil (15.1 mg, 79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.06 (d, *J* = 7.8 Hz, 1H), 6.86 (d, *J* = 7.8 Hz, 1H), 6.68 (s, 1H), 5.18 (s, 1H), 4.81 (s, 1H), 4.00 - 3.80 (m, 3H), 2.87 - 2.68 (m, 5H), 1.72 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  172.0, 150.8, 136.3, 131.3, 125.0, 124.2, 122.1, 119.7, 112.7, 90.5, 79.2, 47.2, 43.5, 27.8,

25.6, 18.1; ESI HRMS calcd for  $C_{16}H_{19}BrN_2O_2 [M + Na]^+$  373.0522, found 373.0527; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1605, 1487, 1456, 1312, 1249, 1158, 1023, 937, 746..

#### (±)-Flustraminol (6)

Following the reported procedure with slight modification<sup>5</sup>, alane-N,N-dimethylethylamine complex (1 M solution in THF, 85 µL, 0.084 mmol) was added to a solution of **53** (15.0 mg, 0.042 mmol) in 2 mL THF under nitrogen at room temperature. The reaction mixture was stirred at the 60 °C for 5 min, treated with 5 mL saturated potassium tartrate, and stirred until the solution became clear. The mixture was extracted with AcOEt and the organic layer was washed with brine, dried and concentrated under reduced pressure. The residue was purified on silica gel column to give flustraminol B (12.5 mg, 87%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.07 (d, *J* = 7.8 Hz, 1H), 6.83 (dd, *J* = 7.8, 1.6 Hz, 1H), 6.62 (s, 1H), 5.19 (d, *J* = 5.8 Hz, 1H), 4.35 (s, 1H), 3.85 (d, *J* = 6.5 Hz, 2H), 2.88 – 2.77 (m, 1H), 2.67 (dd, *J* = 15.8, 7.8 Hz, 1H), 2.54 (s, 3H), 2.29 (dt, *J* = 14.6, 7.4 Hz, 1H), 2.19 – 2.10 (m, 1H), 1.73 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  152.3, 135.43, 131.4, 124.5, 123.7, 120.7, 119.8, 111.2, 95.6, 87.9, 53.1, 46.3, 40.1, 38.8, 25.6, 18.1; ESI HRMS calcd for C<sub>16</sub>H<sub>21</sub>BrN<sub>2</sub>O [M + Na]<sup>+</sup> 359.0729, found 359.0730; IR (CH<sub>2</sub>Cl<sub>2</sub>, cm<sup>-1</sup>) 1673, 1602, 1484, 1444, 1310, 1246, 1158, 1098, 1025, 922, 797.

#### 6. Emission Quenching Experiments – Stern-Volmer Studies

Emission intensities were recorded using a Steady State emission spectra recorded on Horiba Fluorolog<sup>®</sup>-3 model FL1039A/40A spectrofluorometer, equipped with a 450 watt steady state xenon illuminator and single-grating emission monochromator and a photomultiplier tube (room-temperature R928P).

Experimental procedures: All the Eosin Y solutions were excited at 400 nm and the emission intensity was collected at 555 nm. A screw-top quartz cuvette was charged with a 0.1 mM solution of Eosin Y in MeOH (2.0 mL) and the initial emission was collected. Another two series of samples, 0.1 mM Eosin Y in MeOH with compound **12** or DIPEA as quencher in gradient concentrations (5 mM, 10 mM, 15 mM and 20 mM), were tested and the emissions were collected.



#### 7. Light ON - Light OFF Experiments

A flask with septum stopper was charged with substrate **12** (76 mg, 0.2 mmol) in CDCl<sub>3</sub> (5 mL), and Eosin Y (2.5 mg, 0.004 mmol) was added. DIPEA (51 mg, 0.4 mmol) was added via syringe and air was bubbled through the solution for 5 minutes. The flask was irradiated under green LED in the open air for 1 h at which point a reaction aliquot (0.5 mL) was taken via syringe for <sup>1</sup>H NMR analysis. Yields of compound **21** were calculated using anisole as an internal standard. The green LED was switched off and the mixture was stirred in the dark for 1h at which point a reaction aliquot (0.5 mL) was taken for <sup>1</sup>H NMR analysis. The green LED was then switched ON and OFF and ON and OFF alternatively and <sup>1</sup>H NMR yields were calculated using anisole as an internal standard.



#### 8. Crystal Structure Solution and Refinement

Data collection of three structures was performed on a Bruker D8 VENTURE X-ray diffractometer with PHOTON 100 CMOS shutterless detector equipped with a Mo-target X-ray tube ( $\lambda = 0.71073$  Å) at T = 100(2) K. Data reduction and integration were performed with the Bruker software package SAINT (version 8.38A).<sup>6</sup> Data were corrected for absorption effects, using the empirical methods as implemented in SADABS (version 2016/2).<sup>7</sup> The structures were solved by SHELXT (version 2018/2)<sup>8</sup> and refined by full-matrix least-squares procedures using the Bruker SHELXTL (version 2018/3)<sup>9</sup> software package. All non-hydrogen atoms were refined anisotropically. In the structure of Compound **15**, the coordinates of H-atoms on C7 and C10 were refined independently, while other H-atoms were included at calculated positions and refined as riders, with  $U_{iso}(H) = 1.2 U_{eq}(C)$  and  $U_{iso}(H) = 1.5 U_{eq}(C)$  for methyl groups. In the structure of Compound **39**, the coordinates of H-atom on O1 were refined independently, while other H-atoms

were included at calculated positions and refined as riders, with  $U_{iso}(H) = 1.2 U_{eq}(C)$  and  $U_{iso}(H) = 1.5 U_{eq}(C)$  for methyl groups. The structure of Compound **15** was refined as an inversion twin with the parameter of BASF refined to 0.43249. Selected crystallographic data for Compound **15** and **39** are shown in Table S1. Crystallographic data have been deposited with Cambridge Crystallographic Data Centre: Deposition number CCDC 1841089 and 1841090 for Compound **15** and Compound **39**, respectively. Copies of the data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge, CB2 1EZ, UK; Fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk).

	-	
	15	39
Empirical formula	$C_{12}H_{14}N_2O$	$C_{13}H_{16}N_2O_2$
Formula weight	202.25	232.28
Temperature (K)	100(2)	100(2)
Wavelength (Å)	0.71073	0.71073
Crystal system	Orthorhombic	Monoclinic
Space group	$P2_{1}2_{1}2_{1}$	C2/c
<i>a</i> (Å)	5.7386(4)	28.7011(14)
<i>b</i> (Å)	9.5416(7)	9.3880(5)
<i>c</i> (Å)	18.3137(13)	8.9139(4)
α (°)	90.00	90.00
$\beta$ (°)	90.00	99.230(2)
γ(°)	90.00	90.00
$V(\text{\AA}^3)$	1002.77(12)	2370.7(2)
Ζ	4	8
$\rho_{\text{calcd}} (\text{g} \cdot \text{cm}^{-3})$	1.340	1.302
$\mu (\mathrm{mm}^{-1})$	0.087	0.089
<i>F</i> (000)	432	992
Crystal size (mm)	0.08×0.09×0.28	0.06×0.11×0.31
$\theta$ range for data collection (°)	3.083-30.490	2.876-30.582
Reflections collected	12225	56256
Independent reflections	3055	3644
	$[R_{\rm int} = 0.0380]$	$[R_{\rm int} = 0.0409]$
Transmission factors	0.0011/1	0.0644/4
(min/max)	0.9011/1	0.9641/1
Data/restraints/params.	3055/0/147	3644/0/159
$R1,^{a} wR2^{b} (I > 2\sigma(I))$	0.0449, 0.0903	0.0483, 0.1152
$R1$ , <sup>a</sup> $wR2^{b}$ (all data)	0.0572, 0.0960	0.0619, 0.1233
Quality-of-fit <sup>c</sup>	1.052	1.063

Table S1. Crystallographic data for Compound 15 and 39.

 ${}^{a}R1 = \Sigma ||F_{o}| - |F_{c}|| / \Sigma |F_{o}|. {}^{b}wR2 = [\Sigma [w(F_{o}^{2} - F_{c}^{2})^{2}] / \Sigma [w(F_{o}^{2})^{2}]].$ 

<sup>c</sup> Quality-of-fit =  $[\Sigma[w(F_o^2 - F_c^2)^2]/(N_{obs} - N_{params})]^{\frac{1}{2}}$ , based on all data



Figure S1. ORTEP drawing of the Compound 15 drawn with thermal ellipsoids at the 50% probability level. Color scheme used: N blue, O red, C grey, H white.



Figure S2. ORTEP drawing of the Compound 39 drawn with thermal ellipsoids at the 50% probability level. Color scheme used: N blue, O red, C grey, H white.

#### 9. References

[1] K. Wu, Y. Du, T. Wang, Org. Lett. 2017, 19, 5669

[2] P. A. Woods, L. C. Morrill, T. Lebl, A. M. Z. Slawin, R. A. Bragg, A. D. Smith, *Org. Lett.* 2010, **12**, 2660.

[3] D. Li, T. Wu, K. Liang, C. Xia, Org. Lett. 2016, 18, 2228.

[4] J. Davies, T. D. Svejstrup, D. F. Reina, N. S. Sheikh, D. Leonori, J. Am. Chem. Soc. 2016, **138**, 8092.

[5] T. Kawasaki, M. Shinada, D. Kamimura, M. Ohzono, A. Ogawa, Chem. Commun. 2006, 420.

[6] SAINT; part of Bruker APEX3 software package (version 2016.9-0): Bruker AXS, 2016.

[7] SADABS; part of Bruker APEX3 software package (version 2016.9-0): Bruker AXS, 2016.

[8] G. M. Sheldrick, Acta Cryst. 2015, A71, 3-8.

[9] G. M. Sheldrick, Acta Cryst. 2015, C71, 3-8.












































































































































































